 |
|
|
| |
MANAGEMENT OF HEMOGLOBIN DECREASE IN PATIENTS TREATED WITH ABT-450/RITONAVIR/OMBITASVIR AND DASABUVIR WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE-1 INFECTED PATIENTS
|
| |
| |
Reported by Jules Levin
ACG Annual Meeting 2014, Philadelphia, PA, October 21, 2014
Vinod Rustgi, David Bernstein, Thomas Sepe, William King, Moises Diago, Pietro Andreone, Daniel Forton, Hendrik Reesink, Peter Ferenci, Yiran Hu, Jeffrey Enejosa, Daniel Cohen, Yan Luo, Marcos Pedrosa, John Vierling
|
| |
|
|
|
|
|
